Liarozole: A Novel Treatment Approach for Advanced Prostate Cancer - Results of a Large Randomized Trial Versus Cyproterone Acetate
July 1998
in “
Urology
”
Studysummary This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on goldjournal.net →